clinical trials: fact vs. fiction, courtney hudson, ceo & co-founder, emergingmed

Post on 14-Apr-2017

120 Views

Category:

Health & Medicine

0 Downloads

Preview:

Click to see full reader

TRANSCRIPT

Clinical Trials: Fact vs. Fiction

understand your options and the right timing

to consider clinical trials Presented by Courtney Hudson, CEO & Founder, EmergingMed

Ovarian Cancer National Conference | Washington, DC | July 9, 2016

Agenda

1. The basics of clinical trials2. When to search3. What’s available4. About targeted therapies & genomic

profiling5. Considerations for phase I clinical

trials6. Discussion & questions

2

1.800.535.1682

3

What are clinical trials? Measurements of benefits/risks of new

therapies New drug OR drug combination OR

modality OR dosage/sequence OR patient population

Is experimental therapy better or worse or same

Interim analysis and ongoing reviews1.800.535.1682

4

What are clinical trials? Enrollment criteria:

Diagnosis, stage, treatment history, genomic profile

Regimens vs. cycles Phases: 1 1/2 2 2/3 3 Informed consent: you may leave

anytime

1.800.535.1682

Clinical trials may/may not be right for you

Today’s goal: arm you with information to successfully navigate the fast-changing world of ovarian cancer research & clinical trials

Explore clinical trials at each treatment decision

When to search for trials5

OCRFA Clinical Trial Matching Service1. Call a Clinical Trial Navigator

1.800.535.16822. Complete/update profile3. Call trial sites to learn more about trial

matches 4. Review trial matches with your medical

team5. Other resources: ClinicalTrials.gov, your

hospital’s website

6

1.800.535.1682

What’s Available7

8

Studies specifically for ovarian cancer

41 phase 2 and phase 3 studies

16 targeted therapies25 unique targets

&Hundreds of agents in phase I

trialsas of July 8, 2016

Source: EmergingMed database, ClinicalTrials.gov

Clinical trials mirror treatment paradigm

9

3RD LINE…

DIAGNOSIS OR

SUSPICION OF

OVARIAN CANCER

SURGERY

1ST LINE PLATINU

M BASED THERAP

Y 2ND LINEPLATINU

M RESISTA

NT<6

months benefit

2ND LINEPLATINU

M SENSITIV

E

REMISSION

1. Clinical trials expect you receive standard of care (vs. off-label)

2. Narrow window of time to enroll

CONTINUED

REMISSION

SEND TISSUE FOR GENOMIC TESTING

Clinical trials offered at each defined stage

10

3RD LINE…

DIAGNOSIS OR

SUSPICION OF

OVARIAN CANCER

SURGERY

1ST LINE PLATINU

M BASED THERAP

Y 2ND LINEPLATINU

M RESISTA

NT<6

months benefit

2ND LINEPLATINU

M SENSITIV

E

REMISSION

8

24

12

16

untreated

…AND HUNDREDS OF

PHASE I SOLID TUMOR

TRIALS

The business of developing cancer therapies

11

No longer takes 10 years to study a drug

Drug developers may first test new therapies in ‘easier cancers’ before ovarian

Phase I trials for more targeted therapies

1.800.535.1682

Identifying biomarkers specific to your tumor may help you make more informed decisions today…and tomorrow

DNA—RNA—Proteins

About targeted therapies & genomic profiling12

25 molecular targets across 41 ovarian cancer phase II, III studies (as of 7/8/2016)

13

Androgen receptor FLK1 PDGFR

Aromatase FR-alpha SRCBCR/ABL* (BRCA) HIF1-alpha TOP1Cancer stemness

pathways IL2R TOP2CDK4 KDR tubulinCDK6 NADPH VEGFRCHK1 PARP VEGFR2CSK PD-1 Wee1FGFR PDGFR 1.800.535.1682

16 targeted therapies in these 41 studies

14

1.800.535.1682

Unique Targeted Agents US brand name Unique Targeted

AgentsUS brand

name rhuMAb-VEGF / RG435 niraparib

TLC D-99 Doxil, Dox-SL, LipDox, Evacet olaparib Lynparza

bevacizumab Avastin palbociclib Ibrancecediranib Recentin pazopanib Votrientdenileukin difitox Ontak pembrolizumab Keytrudafarletuzumab prexasertibdurvalumab (MEDI4736) regorafenib Stivarganintedanib veliparib

15

Considerations for Phase I trials

Are you 1st, 30th, or 100th patient? First-in-human or testing target

Safety and dosage are tested first, 3-by-3

Anti-cancer activity added as goal 70%+ of all agents move on to

Phase II Over 900 targeted agents in all

cancer studies today (vs 16)WARRANTS A FRESH LOOK AT RISK VS. BENEFIT EQUATION?

OCRFA Clinical Trial Matching Service1. Call a Clinical Trial Navigator

1.800.535.16822. Complete/update profile3. Call trial sites to learn more about trial

matches 4. Review trial matches with your medical

team5. Other resources: ClinicalTrials.gov, your

hospital’s website

16

1.800.535.1682

Courtney Hudsonchudson@emergingmed.com

Questions & Discussion17

top related